WO1989001973A3 - Recombinant pox virus for immunization against tumor-associated antigens - Google Patents

Recombinant pox virus for immunization against tumor-associated antigens Download PDF

Info

Publication number
WO1989001973A3
WO1989001973A3 PCT/US1988/003032 US8803032W WO8901973A3 WO 1989001973 A3 WO1989001973 A3 WO 1989001973A3 US 8803032 W US8803032 W US 8803032W WO 8901973 A3 WO8901973 A3 WO 8901973A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
against tumor
pox virus
immunization against
recombinant pox
Prior art date
Application number
PCT/US1988/003032
Other languages
French (fr)
Other versions
WO1989001973A2 (en
Inventor
Dennis L Panicali
Rene Bernards
Original Assignee
Applied Biotechnology Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Biotechnology Inc, Whitehead Biomedical Inst filed Critical Applied Biotechnology Inc
Publication of WO1989001973A2 publication Critical patent/WO1989001973A2/en
Publication of WO1989001973A3 publication Critical patent/WO1989001973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
PCT/US1988/003032 1987-09-02 1988-09-01 Recombinant pox virus for immunization against tumor-associated antigens WO1989001973A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9203687A 1987-09-02 1987-09-02
US092,036 1987-09-02

Publications (2)

Publication Number Publication Date
WO1989001973A2 WO1989001973A2 (en) 1989-03-09
WO1989001973A3 true WO1989001973A3 (en) 1989-03-23

Family

ID=22231039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003032 WO1989001973A2 (en) 1987-09-02 1988-09-01 Recombinant pox virus for immunization against tumor-associated antigens

Country Status (2)

Country Link
CA (1) CA1341435C (en)
WO (1) WO1989001973A2 (en)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
DE69033975T2 (en) * 1989-01-23 2002-10-02 Chiron Corp Recombinant therapies for infections and hyperproliferative disorders
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
EP0494135B1 (en) * 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
WO1991006658A2 (en) * 1989-10-24 1991-05-16 Cetus Corporation Infective protein delivery system
CA2040099A1 (en) * 1990-05-01 1991-11-02 Mariano Barbacid Tyrosine kinase negative trkb
US5759552A (en) * 1991-03-07 1998-06-02 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
WO1992019266A1 (en) * 1991-05-06 1992-11-12 The United States Of America, As Represented By The Department Of Health And Human Services Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US5545533A (en) * 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
DE4205148A1 (en) * 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh MONOCLONAL ANTIBODY AGAINST C-KIT
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
JPH09503920A (en) 1993-11-18 1997-04-22 チロン ビアジーン，インコーポレイティド Compositions and methods utilizing conditional lethal genes
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
ATE386811T1 (en) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic ALPHAVIRUS VECTOR WITH A REDUCED INHIBITION OF THE SYNTHESIS OF CELL MACROMOLECLES
WO1998000554A1 (en) 1996-07-03 1998-01-08 Genetics Institute, Inc. Protease fmh-1, an ice/ced-like protease
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
DE69838483T2 (en) 1997-10-14 2008-07-03 Darwin Molecular Corp. THYMIDINKINASE MUTANES AND FUSION PROTEINS WITH THYMIDINE KINASE AND GUANYLATEKINASE ACTIVITIES
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
JP2002507387A (en) 1997-12-24 2002-03-12 コリクサ コーポレイション Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
KR20010041992A (en) 1998-03-18 2001-05-25 길리스 스티브 Compounds and methods for therapy and diagnosis of lung cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
BR9910089A (en) 1998-05-01 2004-06-08 Chiron Corp Compositions and antigens of neisseria meningitidis
BR9912671A (en) 1998-08-07 2001-05-02 Univ Washington Immunological antigens for herpes simplex virus and methods for their use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
EP2042598A1 (en) * 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
GB2370573A (en) * 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
ES2310055T3 (en) 1998-12-16 2008-12-16 Novartis Vaccines & Diagnostic CYCLIN DEPENDENT HUMAN KINASE (HPNQALRE).
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
ES2308976T3 (en) 1999-04-02 2008-12-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON.
RU2245366C2 (en) 1999-04-30 2005-01-27 Чирон С.Р.Л. Neisseria antigen, nucleic acid encoding its, their applying
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
PT2289545T (en) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Supplemented omv vaccine against meningococcus
CA2400842C (en) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Novel compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1284740B1 (en) 2000-05-19 2008-05-21 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
CN1911965B (en) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2312649T3 (en) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS.
WO2003053220A2 (en) 2001-12-17 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
DE60324678D1 (en) 2002-07-18 2008-12-24 Univ Washington N T-LYMPHOCYTES AND IDENTIFIED HSV ANTIGENES THEREWITH
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
PT1736541E (en) 2004-03-29 2013-01-31 Galpharma Co Ltd Novel modified galectin 9 protein and use thereof
WO2006019906A1 (en) 2004-07-14 2006-02-23 The Regents Of The University Of California Biomarker for early detection of ovarian cancer
CA2579764A1 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
DK3312272T3 (en) 2004-10-08 2019-12-02 Us Gov Health & Human Services MODULE REPLICATION FITNESS USING A LESS ACTION SYNONYMOUS CODONES
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP2392349A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
ES2381492T3 (en) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedure for prevention or treatment of infection with M. tuberculosis
RU2486204C2 (en) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Cd26 antibodies and methods of using them
UA97469C2 (en) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Humanized cd37-specific binding immunoglobulin molecule
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102481312B (en) 2009-06-05 2015-07-15 传染性疾病研究院 Synthetic Glucopyranosyl Lipid Adjuvants
DK2528621T3 (en) 2010-01-27 2017-01-02 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
EA027236B1 (en) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
US20150030586A1 (en) 2011-06-21 2015-01-29 Sarah Ellen Warren Compositions and methods for the therapy and diagnosis of cancer
CA2846865A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
ES2729967T3 (en) 2012-02-07 2019-11-07 Infectious Disease Res Inst Enhanced adjuvant formulations comprising TLR4 agonists and methods for using them
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
BR112015023500B1 (en) 2013-03-15 2021-01-12 The Regents Of The University Of California pharmaceutical composition
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
CN105209047B (en) 2013-04-18 2020-08-18 免疫设计股份有限公司 GLA monotherapy for cancer treatment
JP2016518126A (en) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Lone Star Virus
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
CA2953917C (en) 2013-07-01 2021-10-19 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3157529B1 (en) 2014-06-17 2021-08-04 The Research Foundation for The State University of New York Ship inhibition to induce activation of natural killer cells
ES2753573T3 (en) 2014-06-27 2020-04-13 Abbott Lab Compositions and methods for detecting human pegivirus 2 (HPGV-2)
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
ES2811523T3 (en) 2016-01-19 2021-03-12 Pfizer Cancer vaccines
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
MX2018014399A (en) 2016-06-01 2019-06-06 Infectious Disease Res Inst Nanoalum particles containing a sizing agent.
PE20200613A1 (en) 2017-07-11 2020-03-11 Pfizer IMMUNOGENIC COMPOSITIONS
KR20200041897A (en) 2017-08-01 2020-04-22 에이비 스튜디오 인코포레이티드 Bispecific antibodies and uses thereof
KR20240023192A (en) 2017-11-24 2024-02-20 유큐(베이징) 바이오파마 코., 엘티디 Anti-OX40 Antibodies and Uses Thereof
CA3091352A1 (en) 2018-02-21 2019-08-29 The University Of Montana Diaryl trehalose compounds and uses thereof
EP3755716A4 (en) 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
CN112566933B (en) 2018-07-20 2023-07-14 祐和医药科技(北京)有限公司 anti-CD 40 antibodies and uses thereof
BR112021004698A2 (en) 2018-09-12 2021-06-01 Eucure (Beijing) Biopharma Co., Ltd anti-tnfrsf9 antibodies and their uses
SG11202105153RA (en) 2018-11-19 2021-06-29 Biocytogen Pharmaceuticals Beijing Co Ltd Anti-pd-1 antibodies and uses thereof
CN117099741A (en) 2019-02-18 2023-11-24 百奥赛图(北京)医药科技股份有限公司 Genetically modified non-human animals with humanized immunoglobulin loci
US20220241410A1 (en) 2019-05-23 2022-08-04 The University Of Montana Vaccine adjuvants based on tlr receptor ligands
WO2021244522A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188637A (en) * 1986-02-07 1987-10-07 Oncogen Vaccines against melanoma

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
J. Gen. Virol. vol. 67, no. 10 (GB) M. Mackett et al.: "Review Article - Vaccinia virus expression vectors" pages 2067-2082 *
Nature, vol. 319, 16 January 1986, C.I. Bargmann et al.: "The neu oncogene encodes an epidermal growth factor receptor-related protein" pages 226-230 *
Nature, vol. 319, 16 January 1986, T. Yamamoto et al.: "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" pages 230-234 *
Nature, vol. 319, 27 Februay 1986, D. Martin-Zanca et al.: "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences" pages 743-748 *
Nature, vol. 326, 30 April 1987, R. Lathe et al.: "Tumour prevention and rejection with recombinant vaccinia" pages 878-880 *
Proc. Natl. Acad. Sci, USA, vol. 83, September 1986 (US) L. Nagarajan et al.: "The human c-ros gene (ROS) is located at chromosome region 6q16-6q22" pages 6568-6572 *
Proc. Natl. Acad. Sci, USA, vol. 84, October 1987 (US) R. Bernards et al.: "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector" pages 6854-6858 *
The EMBO Journal, vol. 6, no. 11, (GB) Y. Yarden et al.: "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand" pages 3341-3351 *

Also Published As

Publication number Publication date
WO1989001973A2 (en) 1989-03-09
CA1341435C (en) 2003-07-29

Similar Documents

Publication Publication Date Title
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
CA2261989A1 (en) Recombinant pox virus for immunization against tumor-associated antigens
WO1995029193A3 (en) Melanoma antigens
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
EP0904393A4 (en) Parapoxvirus vectors
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
EP0332424A3 (en) Chimeric antibodies directed against human carcinoembryonic antigen
AR243080A1 (en) A procedure for obtaining an immunogenic complex of proteins, antigens or peptides, with water-repelling regions and bisdesmosidic regions with water-repelling regions.
NO892251D0 (en) PROCEDURE FOR THE PREPARATION OF COCOCOIDOSE VACCINE BY RECOMBINANT TECHNIQUES.
AU2445888A (en) Recombinant fowlpox virus, vectors for the expression of heterologous proteins and vaccines for poultry derived from this virus
GB9209718D0 (en) Hcg-hlh receptor and hcg-hlh receptor-hch complex as antigens,antibodies thereto and contraceptive vaccine
CA2272338A1 (en) Immunization of infants
CA2101463A1 (en) Recombinant adenovirus vaccines
IT1147844B (en) MALARIA ANTIGEN, PROCEDURE FOR ITS PREPARATION AND VACCINE WITH IT OBTAINED
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
CA2135630A1 (en) Hiv protein epitopes immunologically homologous to hla
EP0327000A3 (en) Gene fragments coding for the variable region of an anti-hiv antibody, chimeric anti-hiv antibodies expressed using the same, and process for their preparation
AU8200791A (en) Ehv-4 glycoprotein vaccine
DK0431327T3 (en) Synthetic vaccine for specific induction of cytotoxic T lymphocytes
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
IL71953A (en) Malaria associated antigen,process for preparation thereof and vaccine comprising it
AU3670697A (en) Recombinant pox virus for immunization against tumor-associated antigens
NZ223624A (en) Peptide immunogen from streptococcus mutans, vaccines and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE